| abstract |
The treatment of an estrogen sensitivencondition by the administration of a selective estrogennreceptor modulator is improved by additionallynadministering a progestationally active compound to thenrecipient. The additional agent can express bothnprogestational and androgenic activity or annandrogenically active material can be employed, ifndesired. Additionally, clomiphene in an array ofnisomeric ratios (EN:ZU) can be used alone for preventionnof osteoporosis, maintenance of a healthful blood lipidnprofile, and prevention of breast tumors, or to sustainnamenorrhea. |